Drug Trial Radar · NCT01088932
Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jul 20, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Mar 2010
Primary completion
Jun 2010
Study completion Jul 2010
Sponsor
- Lead sponsor
- Azevan PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 18, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multiple dose clinical study to be conducted with SRX246 capsules to determine the safety, tolerability and pharmacokinetics of the drug over a 14 day dosing period.
Conditions
- Healthy
Interventions
SRX246Drug
capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety will be determined by performing vital sign measurements, ECGs, complete physical examinations, hematology and clinical chemistry tests, and recording of any reported adverse experiences.Time frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SNBL Clinical Pharmacology Center
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.